These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 24161412

  • 1. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 2. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M, Treur MJ, van der Hel WS, Frequin ST, Groot MT, Verheggen BG.
    J Med Econ; 2012 May; 15(6):1149-58. PubMed ID: 22737996
    [Abstract] [Full Text] [Related]

  • 3. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N, Tambour M, Henriksson F, Fredrikson S.
    J Med Econ; 2013 May; 16(3):349-57. PubMed ID: 23211038
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.
    J Med Econ; 2011 May; 14(5):617-27. PubMed ID: 21777161
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 May; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K, Meyer K, Stafkey-Mailey D, Watson C.
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [Abstract] [Full Text] [Related]

  • 7. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Apr; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 8. NICE rules out NHS prescription of fingolimod for multiple sclerosis.
    Cohen D.
    BMJ; 2011 Aug 10; 343():d5117. PubMed ID: 21831936
    [No Abstract] [Full Text] [Related]

  • 9. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 10; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N, Kim E.
    Clin Ther; 2012 Jul 10; 34(7):1583-90. PubMed ID: 22749258
    [Abstract] [Full Text] [Related]

  • 11. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L.
    Ideggyogy Sz; 2014 Mar 30; 67(3-4):141. PubMed ID: 26118259
    [No Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 30; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 13. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar 30; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 14. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM, Maruszczak MJ, Slater D, Kusel J, Nicholas R, Adlard N.
    J Med Econ; 2017 May 30; 20(5):474-482. PubMed ID: 28008769
    [Abstract] [Full Text] [Related]

  • 15. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ.
    Mult Scler; 2014 Sep 30; 20(10):1381-90. PubMed ID: 24852928
    [Abstract] [Full Text] [Related]

  • 16. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
    Piena MA, Heisen M, Wormhoudt LW, Wingerden JV, Frequin STFM, Uitdehaag BMJ.
    J Med Econ; 2018 Oct 30; 21(10):968-976. PubMed ID: 29911917
    [Abstract] [Full Text] [Related]

  • 17. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 30; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 18. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P, Lundström T, Soini E, Sumelahti ML, Ruutiainen J, Niskala U, Järvinen E.
    Adv Ther; 2020 Feb 30; 37(2):800-818. PubMed ID: 31873868
    [Abstract] [Full Text] [Related]

  • 19. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep 30; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

  • 20. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb 30; 50(2):18-20. PubMed ID: 22329953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.